Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pipobroman→

Pipobroman Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54-91-1
Molecular formula
C10H16Br2N2O2
Molecular weight
356.05 g/mol
Drug class
Polyfunctional alkylating antineoplastic agentpiperazine derivative
Mechanism of action
The precise mechanism is not fully elucidated. It is classified as an alkylating agent and is thought to alkylate DNA, disrupting DNA replication and synthesis and ultimately inducing cell death.
Indications / reported uses
  • Historically used for cytoreductive treatment of polycythaemia vera and essential thrombocythaemia in selected countries; availability and use are jurisdiction-specific and it is not a routine first-line treatment.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4842 · https://pubmed.ncbi.nlm.nih.gov/14565648/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pipobroman Environmental Risk Assessment (ERA) (the Pipobroman ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.